IBDEI0LI ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10196,0)
 ;;=908.3^^44^561^17
 ;;^UTILITY(U,$J,358.3,10196,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10196,1,3,0)
 ;;=3^Carotid Cavernous Fistula,Late Effect
 ;;^UTILITY(U,$J,358.3,10196,1,4,0)
 ;;=4^908.3
 ;;^UTILITY(U,$J,358.3,10196,2)
 ;;=^275249
 ;;^UTILITY(U,$J,358.3,10197,0)
 ;;=368.2^^44^562^24
 ;;^UTILITY(U,$J,358.3,10197,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10197,1,3,0)
 ;;=3^Diplopia
 ;;^UTILITY(U,$J,358.3,10197,1,4,0)
 ;;=4^368.2
 ;;^UTILITY(U,$J,358.3,10197,2)
 ;;=^35208
 ;;^UTILITY(U,$J,358.3,10198,0)
 ;;=695.3^^44^562^2
 ;;^UTILITY(U,$J,358.3,10198,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10198,1,3,0)
 ;;=3^Acne Rosacea
 ;;^UTILITY(U,$J,358.3,10198,1,4,0)
 ;;=4^695.3
 ;;^UTILITY(U,$J,358.3,10198,2)
 ;;=Acne Rosacea^107114
 ;;^UTILITY(U,$J,358.3,10199,0)
 ;;=250.00^^44^562^22
 ;;^UTILITY(U,$J,358.3,10199,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10199,1,3,0)
 ;;=3^DM type II w/o Eye Disease
 ;;^UTILITY(U,$J,358.3,10199,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,10199,2)
 ;;=DM type II w/o Eye Disease^33605
 ;;^UTILITY(U,$J,358.3,10200,0)
 ;;=346.90^^44^562^41
 ;;^UTILITY(U,$J,358.3,10200,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10200,1,3,0)
 ;;=3^Headache,Migraine-Not Intractable
 ;;^UTILITY(U,$J,358.3,10200,1,4,0)
 ;;=4^346.90
 ;;^UTILITY(U,$J,358.3,10200,2)
 ;;=Migraine without Intract^293880
 ;;^UTILITY(U,$J,358.3,10201,0)
 ;;=376.30^^44^562^30
 ;;^UTILITY(U,$J,358.3,10201,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10201,1,3,0)
 ;;=3^Exophthalmos,NOS
 ;;^UTILITY(U,$J,358.3,10201,1,4,0)
 ;;=4^376.30
 ;;^UTILITY(U,$J,358.3,10201,2)
 ;;=Exophthalmos NOS^43683
 ;;^UTILITY(U,$J,358.3,10202,0)
 ;;=368.8^^44^562^7
 ;;^UTILITY(U,$J,358.3,10202,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10202,1,3,0)
 ;;=3^Blurred Vision
 ;;^UTILITY(U,$J,358.3,10202,1,4,0)
 ;;=4^368.8
 ;;^UTILITY(U,$J,358.3,10202,2)
 ;;=Blurred Vision^88172
 ;;^UTILITY(U,$J,358.3,10203,0)
 ;;=362.34^^44^562^5
 ;;^UTILITY(U,$J,358.3,10203,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10203,1,3,0)
 ;;=3^Amaurosis Fugax
 ;;^UTILITY(U,$J,358.3,10203,1,4,0)
 ;;=4^362.34
 ;;^UTILITY(U,$J,358.3,10203,2)
 ;;=^268622
 ;;^UTILITY(U,$J,358.3,10204,0)
 ;;=368.13^^44^562^88
 ;;^UTILITY(U,$J,358.3,10204,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10204,1,3,0)
 ;;=3^Photophobia
 ;;^UTILITY(U,$J,358.3,10204,1,4,0)
 ;;=4^368.13
 ;;^UTILITY(U,$J,358.3,10204,2)
 ;;=^126851
 ;;^UTILITY(U,$J,358.3,10205,0)
 ;;=368.40^^44^562^113
 ;;^UTILITY(U,$J,358.3,10205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10205,1,3,0)
 ;;=3^Vis Field Defect
 ;;^UTILITY(U,$J,358.3,10205,1,4,0)
 ;;=4^368.40
 ;;^UTILITY(U,$J,358.3,10205,2)
 ;;=^126859
 ;;^UTILITY(U,$J,358.3,10206,0)
 ;;=369.4^^44^562^58
 ;;^UTILITY(U,$J,358.3,10206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10206,1,3,0)
 ;;=3^Legally Blind,USA Definition
 ;;^UTILITY(U,$J,358.3,10206,1,4,0)
 ;;=4^369.4
 ;;^UTILITY(U,$J,358.3,10206,2)
 ;;=Legal Blindness^268887
 ;;^UTILITY(U,$J,358.3,10207,0)
 ;;=250.01^^44^562^21
 ;;^UTILITY(U,$J,358.3,10207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10207,1,3,0)
 ;;=3^DM Type I w/o Eye Disease
 ;;^UTILITY(U,$J,358.3,10207,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,10207,2)
 ;;=Diabetes Mellitus Type I^33586
 ;;^UTILITY(U,$J,358.3,10208,0)
 ;;=V08.^^44^562^40
 ;;^UTILITY(U,$J,358.3,10208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10208,1,3,0)
 ;;=3^HIV Positive
 ;;^UTILITY(U,$J,358.3,10208,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,10208,2)
 ;;=Asymptomatic HIV Status^303392
 ;;^UTILITY(U,$J,358.3,10209,0)
 ;;=921.0^^44^562^16
 ;;
 ;;$END ROU IBDEI0LI
